{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:47:57Z","timestamp":1785840477630,"version":"3.56.0"},"reference-count":24,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Krystal Biotech"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Recessive dystrophic epidermolysis bullosa is a severe inherited blistering disorder characterized by chronic wounds, fibrosis and systemic complications. Beremagene geperpavec (B-VEC), a topical HSV1-based gene therapy delivering full-length COL7A1, has shown efficacy in clinical trials; however, real-world data remain limited. This retrospective, descriptive case series reports on three patients with genetically confirmed recessive dystrophic epidermolysis bullosa \u2013 two children and one young adult \u2013 treated between 2024 and 2026 at two Italian tertiary centres. All patients had extensive chronic skin involvement and received weekly topical B-VEC. Clinical data included wound characteristics, response to therapy, supportive care and adverse events. All patients showed clinically meaningful improvement in target wound healing. One child achieved ~70% reduction in the wound area needing treatment; the second had ~50% with shallower morphology and reduced bleeding. The adult, previously enrolled in the GEM-3 trial, achieved over 60% wound closure after reinitiating B-VEC via Italy\u2019s 5% Italian Medicines Agency (AIFA) access programme. No treatment-related adverse events occurred. Adjunctive care included wound hygiene optimization, nutritional and iron support, and pain control. In this small descriptive case series, B-VEC was well tolerated and associated with clinically meaningful improvement in wound healing though outcomes were more variable and, in some cases, less pronounced than those reported in pivotal trials, nevertheless supporting its integration into a comprehensive care model that addresses infection risk, anaemia, nutrition, and wound management.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-topical-gene-therapy-for-severe-recessive-dystrophic-epidermolysis-bullosa-clinical-outcomes-and-multidisciplinary-management-in-three-patients-treated-with-beremagene-geperpa<\/jats:p>","DOI":"10.7573\/dic.2026-2-4","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:03:03Z","timestamp":1785837783000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Topical gene therapy for severe recessive dystrophic epidermolysis bullosa: clinical outcomes and multidisciplinary management in three patients treated with beremagene geperpavec (B-VEC) in Italy \u2013 a case series"],"prefix":"10.7573","author":[{"given":"Michela","family":"Brena","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/016zn0y21","id-type":"ROR","asserted-by":"publisher"}],"name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Guez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/016zn0y21","id-type":"ROR","asserted-by":"publisher"}],"name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Lospalluti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tGuide SV, Gonzalez ME, Ba\u011fc\u0131 IS, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med 2022;387:2211\u20132219. https:\/\/doi.org\/10.1056\/NEJMoa2206663","DOI":"10.1056\/NEJMoa2206663"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tPaller AS, Guide SV, Ayala D, et al. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa. J Dermatolog Treat 2024;35:2350232. https:\/\/ doi.org\/10.1080\/09546634.2024.2350232","DOI":"10.1080\/09546634.2024.2350232"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tPayne AS. Topical gene therapy for epidermolysis bullosa. N Engl J Med 2022;387:2281\u20132284. https:\/\/doi.org\/10.1056\/ NEJMe2213203","DOI":"10.1056\/NEJMe2213203"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tSchaffer DV. The coming of age of topical gene therapy for dystrophic epidermolysis bullosa. N Engl J Med 2022;387:2279\u20132280. https:\/\/doi.org\/10.1056\/NEJMe2212899","DOI":"10.1056\/NEJMe2212899"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tRetrosi C, Diociaiuti A, De Ranieri C, et al. Multidisciplinary care for patients with epidermolysis bullosa from birth to adolescence: experience of one Italian reference center. Ital J Pediatr 2022;48:58. https:\/\/doi.org\/10.1186\/ s13052-022-01252-3","DOI":"10.1186\/s13052-022-01252-3"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tFine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol 2009;61:387\u2013402; quiz 403\u2013404. https:\/\/doi.org\/10.1016\/j.jaad.2009.03.053","DOI":"10.1016\/j.jaad.2009.03.053"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tBonamonte D, Filoni A, De Marco A, et al. Squamous cell carcinoma in patients with inherited epidermolysis bullosa: review of current literature. Cells 2022;11:1365. https:\/\/doi.org\/10.3390\/cells11081365","DOI":"10.3390\/cells11081365"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tHas C, El Hachem M, Bu\u010dkov\u00e1 H, et al. Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases. J Eur Acad Dermatol Venereol 2021;35:2349\u20132360. https:\/\/doi.org\/10.1111\/jdv.17629","DOI":"10.1111\/jdv.17629"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tFine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry. JAMA Dermatol 2016;152:1231\u20131238. https:\/\/doi.org\/10.1001\/ jamadermatol.2016.2473","DOI":"10.1001\/jamadermatol.2016.2473"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tEichstadt S, Tang JY, Solis DC, et al. From clinical phenotype to genotypic modelling: incidence and prevalence of recessive dystrophic epidermolysis bullosa (RDEB). Clin Cosmet Investig Dermatol 2019;12:933\u2013942. https:\/\/doi.org\/ 10.2147\/CCID.S232547","DOI":"10.2147\/CCID.S232547"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tFeinstein JA, Jambal P, Peoples K, et al. Assessment of the timing of milestone clinical events in patients with epidermolysis bullosa from North America. JAMA Dermatol 2019;155:196\u2013203. https:\/\/doi.org\/10.1001\/ jamadermatol.2018.4673","DOI":"10.1001\/jamadermatol.2018.4673"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tHas C, Hess M, Anem\u00fcller W, et al. Epidemiology of inherited epidermolysis bullosa in Germany. J Eur Acad Dermatol Venereol 2023;37:402\u2013410. https:\/\/doi.org\/10.1111\/jdv.18637","DOI":"10.1111\/jdv.18637"},{"key":"ref12","unstructured":"13.\tTabor A, Pergolizzi JV, Marti G, et al. Raising awareness among healthcare providers about epidermolysis bullosa and advancing toward a cure. J Clin Aesthet Dermatol 2017;10:36\u201348."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tBruckner AL, Losow M, Wisk J, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis 2020;15:1. https:\/\/doi.org\/10.1186\/s13023-019-1279-y","DOI":"10.1186\/s13023-019-1279-y"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tGurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med 2022;28:780\u2013788. https:\/\/doi.org\/10.1038\/s41591-022-01737-y","DOI":"10.1038\/s41591-022-01737-y"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tMarinkovich MP, Paller AS, Guide SV, et al. Long-term safety and tolerability of beremagene geperpavec-svdt (B-VEC) in an open-label extension study of patients with dystrophic epidermolysis bullosa. Am J Clin Dermatol 2025;26:623\u2013635. https:\/\/doi.org\/10.1007\/s40257-025-00942-y","DOI":"10.1007\/s40257-025-00942-y"},{"key":"ref16","unstructured":"17.\tItalian Medicines Agency. Guidelines for the classification and conduct of observational drug studies. https:\/\/www. aifa.gov.it\/documents\/20142\/1654269\/Det-Pres-425-2024-Linea_Guida_osservazionali.pdf. Accessed May 9, 2025."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tNatsuga K, Tsuruta D, Takashima S, et al. Efficacy and safety of the topical gene therapy beremagene geperpavec-svdt (B-VEC) in an open-label study of Japanese subjects with dystrophic epidermolysis bullosa. J Dermatol 2025;52:1494\u20131502. https:\/\/doi.org\/10.1111\/1346-8138.17863","DOI":"10.1111\/1346-8138.17863"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tKarakioulaki M, Eyerich K, Has C. Beremagene geperpavec (B-VEC) for infantile dystrophic epidermolysis bullosa: benefit of early intervention. J Eur Acad Dermatol Venereol 2025;40(5):e293\u2013e295. https:\/\/doi.org\/10.1111\/jdv.70028","DOI":"10.1111\/jdv.70028"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tKern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol 2023;188:12\u201321. https:\/\/doi.org\/10.1093\/bjd\/ljac001","DOI":"10.1093\/bjd\/ljac001"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tPilo C, Benedan L, Morra V, et al. Quality of life in children and adults with epidermolysis bullosa: the QoL-REB explorative study. Orphanet J Rare Dis 2026; 21(1):181\u2013188. https:\/\/doi.org\/10.1186\/s13023-026-04321-6","DOI":"10.1186\/s13023-026-04321-6"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tTorres Pradilla M, \u00c1lvarez E, Novoa M, et al. Oleogel-S10 in dystrophic epidermolysis bullosa: a case series evaluating the impact on wound burden over two years. Adv Ther 2024;41:867\u2013877. https:\/\/doi.org\/10.1007\/ s12325-023-02749-x","DOI":"10.1007\/s12325-023-02749-x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tDavidovic M, Gewert S, Has C. Real-world experience with Oleogel-S10 for wounds in epidermolysis bullosa. JEADV Clin Pract 2026;5:184\u2013187. https:\/\/doi.org\/10.1002\/jvc2.70162","DOI":"10.1002\/jvc2.70162"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tCollins A, Myers EM, Derrick KM, et al. Real-world case series: birch triterpenes gel efficacy in 2 patients with junctional epidermolysis bullosa. JAAD Case Rep 2025;61:146\u2013149. https:\/\/doi.org\/10.1016\/j.jdcr.2025.03.020","DOI":"10.1016\/j.jdcr.2025.03.020"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/08\/dic.2026-2-4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:03:24Z","timestamp":1785837804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/topical-gene-therapy-for-severe-recessive-dystrophic-epidermolysis-bullosa-clinical-outcomes-and-multidisciplinary-management-in-three-patients-treated-with-beremagene-geperpavec-b-vec-in-italy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-2-4","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"dic.2026-2-4"}}